VU Chenbin (US),ВУ Ченбин (US),DIKSON Richard V. (US),ДИКСОН Ричард В. (US),BELK Dzhonatan P. (US),БЕЛК Джонатан П. (US),IN Khua (US),ИН Хуа (US),ARDZHIRIADI Mariya A. (US),АРДЖИРИАДИ Мария А. (US),KA,VU Chenbin,ВУ Ченбин,DIKSON Richard V.,ДИКСОН Ричард В.,BELK Dzhonatan P.,БЕЛК Джонатан П.,IN Khua,ИН Хуа,ARDZHIRIADI Mariya A.,АРДЖИРИАДИ Мария А.,KAFF Kerolin A.,КАФФ Кэролин А.,KHINTON Pol R.,ХИНТО
申请号：
RU2016132208
公开号：
RU0002650767C2
申请日:
2016.08.05
申请国别(地区):
RU
年份:
2018
代理人:
摘要：
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Recombinant antibody or antigen-binding fragment thereof is described. This antibody binds IL-13, contains two variable domains, wherein one variable domain comprises the amino acid sequence of SEQ ID NO:80, and the other variable domain comprises the amino acid sequence of SEQ ID NO:81. In addition, said antibody comprises a human heavy chain constant region IgG1 comprising a hinge region comprising replacing leucine with alanine at position 234 (EU numbering) and the replacement of leucine with alanine at position 235 (EU numbering), also contains a constant region of light kappa of the human chain. This antibody blocks the binding of IL-13 to IL-13Rα1 and IL-13Rα2 and is capable of binding to a human IL-13 variant in which the arginine residue at position 130 in SEQ ID NO:1 replaced by the remainder of glutamine. Also described is a nucleic acid encoding a recombinant antibody or its antigen-binding fragment, replication and expression vectors containing such a nucleic acid. Host cells containing these vectors are described. Method for producing antibody or antigen-binding fragment thereof, capable of binding IL-13, including culturing the host cell. Also described is a pharmaceutical composition for treating IL-13 associated disorder that comprises effective amount of a recombinant antibody. Method is provided for treating a subject from a disorder in which the activity of IL-13 is deleterious, comprising the step of administering to the subject antibody or antigen-binding fragment thereof.EFFECT: inventions are useful for detection of hIL-13 and for inhibiting activity of hIL-13, for example in a human suffering from disorder in which hIL-13 activity adversely affects health.32 cl, 23 tbl, 2 exИзобретение относится к биохимии. Описано рекомбинантное антитело или его антигенсвязывающий фрагмент. Указанное антитело связывает IL-13, содержит два вариабельных домена, где один вариабельный домен содер
